On October 8th Gilead Sciences (GILD.US) said it had signed a joint procurement agreement with the European Union for 500,000 Redsiway. The agreement will cover drug purchases from 37 countries over the next six months, including 27 EU countries, the UK, six Balkan semi-Japanese countries and other EEA countries (Iceland, Liechtenstein and Norway). The cost will be paid by the country that purchased the drug, and the agreement also includes the option to extend the term.
It comes after several European countries said they were facing a shortage of drugs, raising concerns about how to control the spread of a second wave of health events.
As winter approaches, more and more people are choosing to stay indoors, with a sharp increase in new cases in European countries including Belgium, France and the Netherlands. Spain has one of the highest numbers of people infected in Europe, with nearly 10,700 people hospitalized as of Tuesday for health reasons.
It is reported that the European Commission has previously agreed to provide about 3,400 patients with more than 20,000 additional doses of Rydersiwe on top of the initial 30,000 courses.
Gilead Sciences said the new agreement, which replaced the original agreement funded by the European Commission’s Emergency Response Fund (ESI), would fulfil the order from Monday. The deal will help allay concerns about Redsiwe’s availability after the company pledged to sell most of its products to the U.S. market this summer.
The U.S. drugmaker expanded production as demand soared after studies in clinical trials showed the drug helped shorten hospital recovery times. The company said it expects to produce more than 2 million treatments this year.